



## **Ultragenyx to Participate in Investor Conferences in September**

August 29, 2024 8:30 PM EDT

*Morgan Stanley 22<sup>nd</sup> Annual Global Healthcare Conference on September 4*

*Cantor Global Healthcare Conference on September 17*

*Bank of America Global Healthcare Conference on September 18*

NOVATO, Calif., Aug. 29, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultrarare genetic diseases, today announced participation in three upcoming investor conferences.

### **Morgan Stanley 22<sup>nd</sup> Annual Global Healthcare Conference (New York, NY)**

- Wednesday, September 4, 2024, Emil Kakkis, M.D., Ph.D., CEO and President, will participate in a fireside chat and host 1x1 meetings.

### **Cantor Global Healthcare Conference (New York, NY)**

- Tuesday, September 17, 2024, Emil Kakkis and Howard Horn, Chief Financial Officer, will participate in a fireside chat and host 1x1 meetings.

### **Bank of America Global Healthcare Conference (London, UK)**

- Wednesday, September 18, 2024, Eric Crombez, M.D., Chief Medical Officer and Joshua Higa, Vice President, Investor Relations, will participate in a fireside chat and host 1x1 meetings.

The live and archived webcast of the fireside chats will be accessible from the company's website at <https://ir.ultragenyx.com/events-presentations>.

About Ultragenyx Pharmaceutical Inc.

Ultragenyx is a biopharmaceutical company committed to bringing novel products to patients for the treatment of serious rare and ultrarare genetic diseases. The company has built a diverse portfolio of approved therapies and product candidates aimed at addressing diseases with high unmet medical need and clear biology for treatment, for which there are typically no approved therapies treating the underlying disease.

The company is led by a management team experienced in the development and commercialization of rare disease therapeutics. Ultragenyx's strategy is predicated upon time- and cost-efficient drug development, with the goal of delivering safe and effective therapies to patients with the utmost urgency.

For more information on Ultragenyx, please visit the company's website at: [www.ultragenyx.com](http://www.ultragenyx.com).

Contacts – Ultragenyx Pharmaceutical, Inc.

Investors  
Joshua Higa  
[ir@ultragenyx.com](mailto:ir@ultragenyx.com)